-
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res. 2026 Mar 16; 32(6):1157-1168. Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ. PMID: 41537704; PMCID: PMC12912800.
-
Addition of pulsed electric field ablation to SBRT for lung tumors: effect on health-related quality of life. Lung Cancer Manag. 2026 Dec; 15(1):2635332. Harris JP, Boyd C, Shi M, Reilly M, Simon A, Seyedin SN, Chen WP, Nagasaka M, Abi-Jaoudeh N, Hoyt MA. PMID: 41783980; PMCID: PMC12969734.
-
JIN-A02, a Mutant-Selective Fourth-Generation EGFR inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. Clin Cancer Res. 2026 Feb 06. Lee EJ, Ko JA, Kim MJ, Cho JS, Han JY, Kim SW, Lee KH, Shim BY, Sun JM, Nagasaka M, Park S, Oh SY, Hong MH, Lee JB, Jo A, Seah E, Cho BC, Lim SM. PMID: 41649868.
-
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial. Nat Med. 2026 Feb; 32(2):682-689. Besse B, Lin JJ, Bazhenova L, Goto K, de Langen AJ, Kim DW, Wolf J, Springfeld C, Popat S, Lim DWT, Nagasaka M, Hong JY, Baik CS, Hervieu A, Moreno V, Yang N, Kollengode K, Yang H, Xu Y, Calvet CY, Yuan Y, Hammell AB, Drilon A, Solomon BJ. PMID: 41639379; PMCID: PMC12920079.
-
An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer. Expert Rev Anticancer Ther. 2026 Jan 18. Samaeekia R, Arter Z, Nagasaka M. PMID: 41548253.
-
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report. Lung Cancer (Auckl). 2025; 16:199-203. Lee ATM, Park CJ, Arter ZL, Nagasaka M, Ou SI. PMID: 41477303; PMCID: PMC12747890.
-
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions. JCO Precis Oncol. 2025 Aug; 9:e2500221. Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram AM, Gadgeel SM, Ma PC, Konduri K, Nguyen D, Misleh J, Bleeker J, Weiss M, Thavaneswaran S, Haura EB, Deegan M, Kaufman J, Srivastava J, Jansen VM, Liu SV. PMID: 41428976; PMCID: PMC12736398.
-
Harmonizing the DESTINY and Broadening the HORIZON of HER2 ADCs in the Face of Next-Generation HER2 TKI for the Treatment Options of HER2 mutations positive (HER2+) NSCLC. J Thorac Oncol. 2025 Dec; 20(12):1737-1740. Xu Y, Nagasaka M, Ou SI, Li M. PMID: 41350038.
-
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges. Signal Transduct Target Ther. 2025 Nov 28; 10(1):385. Choucair K, Imtiaz H, Uddin MH, Nagasaka M, Al-Hallak MN, Philip PA, El-Rayes B, Pasche BC, Azmi AS. PMID: 41309533; PMCID: PMC12660860.
-
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma. bioRxiv. 2025 Nov 25. Khan HY, Al Hallak MN, Aboukameel A, Bannoura SF, Uddin MH, Aboukameel AA, Alkan FK, Caglayan AB, Alkan HK, Bao B, Jimenez H, Johansen AM, McGrath C, Barker G, Choucair K, Tubon M, Beal E, Kim S, Beydoun R, Dyson G, Shi Y, Nagasaka M, Atfi A, Korkaya H, Saif MW, Philip PA, El-Rayes B, Chen H, Shields AF, Mohammad RM, Pasche BC, Azmi AS. PMID: 41394580; PMCID: PMC12697726.
-
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study. J Natl Compr Canc Netw. 2025 Nov 19; 23(12):522-530. Waliany S, Roy SG, Pecci F, Weber UM, Sun F, Arter Z, Lomibao M, Alessi JV, Nishino M, Luo F, Repetto M, Falcon C, Do A, Peterson J, Liang J, Liu A, Nagasaka M, Ricciuti B, Drilon A, Ou SI, Neal JW, Patil T, Awad M, Yeap BY, Digumarthy SR, Lin JJ. PMID: 41671458.
-
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials. JAMA Netw Open. 2025 Nov 03; 8(11):e2543107. Jänne PA, Planchard D, Goto K, Smit EF, de Langen AJ, Goto Y, Ninomiya K, Kubo T, Pérol M, Felip E, Hayashi H, Nakagawa K, Shimizu J, Nagasaka M, Pereira K, Taguchi A, Ali A, Karnoub M, Yonemochi R, Leung D, Li BT. PMID: 41222935; PMCID: PMC12612940.
-
Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on Gilteritnib. Lung Cancer (Auckl). 2025; 16:139-145. Ou SI, Park CJ, Arter ZL, Nagasaka M. PMID: 41158152; PMCID: PMC12555016.
-
Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2026 Mar; 27(2):189-196.e1. Gadgeel SM, Nagasaka M, Dziubek K, Braun T, Hassan K, Cheng H, Halmos B, Wozniak A, Stevenson J, Patil P, Pennell N, Fidler MJ, Qin A, Niu Z, Nagrath S, Kalemkerian GP. PMID: 41046186.
-
Early checkpoint inhibition before chemoradiation: is the strategy ready for stage III non-small cell lung cancer? Transl Lung Cancer Res. 2025 Sep 30; 14(9):4159-4164. Hasan N, Harris JP, Nagasaka M. PMID: 41133011; PMCID: PMC12541875.
-
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nat Commun. 2025 Aug 19; 16(1):7717. Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. PMID: 40830141; PMCID: PMC12365225.
-
XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how? Transl Lung Cancer Res. 2025 Aug 31; 14(8):2895-2899. Nagasaka M, Khan HY, Luo F, Al-Hallak MN, Saif MW, Mohammad RM, Azmi AS. PMID: 40948839; PMCID: PMC12432644.
-
The development of Zongertinib for HER2-mutant NSCLC. Crit Rev Oncol Hematol. 2025 Nov; 215:104896. Brazel D, Park CJ, Nagasaka M. PMID: 40816594.
-
Pilot Study of Combining Stereotactic Body Radiation Therapy with Pulsed Field Ablation for Oligometastatic/Oligoprogressive Lung Tumors. J Vasc Interv Radiol. 2025 11; 36(11):1687-1695. Harris JP, Boyd C, Shi M, Reilly M, Simon A, Seyedin SN, Chen WP, Nagasaka M, Nabar R, Abi-Jaoudeh N. PMID: 40803526; PMCID: PMC12582577.
-
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation. Cell Rep Med. 2025 May 20; 6(5):102121. Xu Y, Yang JC, Zhao Y, Doucet L, Zhou J, Wang Y, Planchard D, Fan Y, Jin B, Han Z, Greillier L, Mazieres J, Sun M, Hu Y, Song X, Ding C, Wu L, Tang K, Liang L, Yao Y, Cheng Y, He Y, Ferreira BP, Ghiringhelli F, Felip E, Bosch-Barrera J, Liu A, Yu Y, Dong X, Gao J, Camidge DR, Nian W, Zhou C, Yang R, John T, Gao B, Bazhenova L, Nagasaka M, Wang J, Ren X, Xu F, Li W, Zhao D, Wang H, Sun S, Huang J, Zhu X, Zheng L, Jänne PA, Wang M. PMID: 40334661; PMCID: PMC12147912.
-
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations. JCO Oncol Adv. 2025; 2(1):e2400032. Azar I, Khan HY, Bannoura SF, Gandhi N, Uddin MH, Nagasaka M, Gong J, Nazha B, Choucair K, Vojjala N, Khushman MM, Soares HP, El-Deiry WS, Philip PA, El-Rayes B, Chen H, Lou E, Muqbil I, Farrell AP, Swensen J, Oberley MJ, Nabhan C, Goel S, Shields AF, Mohammad RM, Pasche BC, Azmi AS. PMID: 40330142; PMCID: PMC12052073.
-
Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes. JCO Oncol Adv. 2025; 2(1):00022. Nagasaka M, Warnecke B, Ou SI, Bannoura SF, Kim C, Elliott A, Halmos B, Hoon D, Darabi S, Sukari A, Radovich M, Lou E, Sledge G, El-Deiry W, Al-Hallak MN, Pasche BC, Azmi AS. PMID: 40330141; PMCID: PMC12052079.
-
Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors. Cardiooncology. 2025 Apr 28; 11(1):40. Sayer M, Hamano H, Nagasaka M, Lee BJ, Doh J, Patel PM, Zamami Y, Ozaki AF. PMID: 40296103; PMCID: PMC12036232.
-
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154). Lung Cancer (Auckl). 2025; 16:51-55. Luo FX, Arter Z, Ou SI, Nagasaka M. PMID: 40313586; PMCID: PMC12044223.
-
Consideration of Pneumonectomy in the Era of Chemo-Immunotherapy in Resectable NSCLC. Thorac Cardiovasc Surg Rep. 2025 Jan; 14(1):e1-e3. Azar I, Vojjala N, Parikh R, Keshava HB, Nagasaka M. PMID: 40291820; PMCID: PMC12020623.
-
Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC). Expert Rev Anticancer Ther. 2025 Jun; 25(6):711-718. Raez LE, Baca Y, Ribeiro JR, Nieva JJ, Mamdani H, Lopes G, Borghaei H, Socinski M, Wozniak AJ, Vanderwalde A, Uribe CC, Sumarriva D, Khan H, Liu SV, Nagasaka M. PMID: 40237370.
-
Oncogenic gene fusions in cancer: from biology to therapy. Signal Transduct Target Ther. 2025 Apr 14; 10(1):111. Liu SV, Nagasaka M, Atz J, Solca F, Müllauer L. PMID: 40223139; PMCID: PMC11994825.
-
Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025 Jun; 43(16):1920-1929. Pérol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C. PMID: 40179330; PMCID: PMC12118623.
-
The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC. Future Oncol. 2025 Apr; 21(9):1005-1011. Nagasaka M, Roy UB, Berk A, Liu G, Nadler E, Abrahami D. PMID: 40084656; PMCID: PMC11988244.
-
Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: A systematic review. Crit Rev Oncol Hematol. 2025 Jun; 210:104676. Hasan N, Yazdanpanah O, Harris JP, Nagasaka M. PMID: 40064250.
-
Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy. Cardiooncology. 2025 Mar 05; 11(1):26. Ozaki AF, Sayer M, Hamano H, Nagasaka M, Lee BJ, Doh J, Naqvi A, Nowrouzi N, Zamami Y, Patel PM. PMID: 40045435; PMCID: PMC11881249.
-
Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer. Expert Rev Respir Med. 2025 Feb 20; 1-10. Hasan N, Nagasaka M. PMID: 39965618.
-
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC. Lung Cancer (Auckl). 2025; 16:1-9. Arter ZL, Shieh K, Nagasaka M, Ou SI. PMID: 39995769; PMCID: PMC11847431.
-
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025 Feb 06; 392(6):566-576. Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A, eNRGy Investigators. PMID: 39908431; PMCID: PMC11878197.
-
The User's Guide to Amivantamab. Target Oncol. 2025 Mar; 20(2):235-245. Brazel D, Smith J, Ou SI, Nagasaka M. PMID: 39903428; PMCID: PMC11933153.
-
Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets. Cancer Med. 2025 Feb; 14(4):e70665. Arter ZL, Lee ATM, Nagasaka M, Ou SI. PMID: 39950716; PMCID: PMC11826831.
-
Consolidation ALK Tyrosine Kinase Inhibitor in Definitively Treated Unresectable Stage III ALK+ NSCLC: Can Real-World Data Inform Clinical Decision in the Absence of a LAURA-Type Designed Trial? J Thorac Oncol. 2025 Jan; 20(1):12-16. Arter ZL, Ou SI, Nagasaka M. PMID: 39794098.
-
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC. Lung Cancer (Auckl). 2024; 15:169-176. Lee ATM, Nagasaka M. PMID: 39717628; PMCID: PMC11664093.
-
Adagrasib in the Treatment of KRAS p.G12C Positive Advanced NSCLC: Design, Development and Place in Therapy. Drug Des Devel Ther. 2024; 18:5673-5683. Warnecke B, Nagasaka M. PMID: 39654605; PMCID: PMC11626957.
-
Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database. Cancer Med. 2024 Dec; 13(24):e70272. Waliany S, Nagasaka M, Park L, Lam C, Jiang Z, Lin F, Neal JW. PMID: 39692700; PMCID: PMC11653943.
-
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review. J Thorac Oncol. 2025 Apr; 20(4):465-474. Xia Y, Wang K, Zhao J, Arter Z, Zhang Y, Zhou J, Lu Y, Zeng L, Du R, Owens JA, Elamin YY, Gay CM, Skoulidis F, Tsao AS, Lu C, Cascone T, Gibbons DL, Zhang J, Chen O, Mok KKS, Nagasaka M, Li W, Heymach JV, Ou SI, Li M, Le X. PMID: 39622411.
-
Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors. Oncologist. 2024 Nov 04; 29(11):e1480-e1491. Morgenstern-Kaplan D, Kareff SA, Trabolsi A, Rodriguez E, Krause H, Ribeiro JR, Tan H, Antonarakis ES, Lou E, Nagasaka M, Algaze S, Lenz HJ, Liu SV, Halmos B, Hoon DSB, Seeber A, Ma PC, El-Deiry WS, Vanderwalde AM, Lopes G. PMID: 38986529; PMCID: PMC11546728.
-
Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma. JCO Precis Oncol. 2024 Oct; 8:e2400334. Kroening G, Luo J, Evans MG, Adeyelu T, Ou SI, Arter ZL, Wise-Draper TM, Sukari A, Azmi AS, Braxton DR, Elliott A, Bryant DA, Oberley MJ, Kim C, Shapiro GI, French CA, Nagasaka M. PMID: 39447095; PMCID: PMC11520346.
-
Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis. Cancer Treat Rev. 2024 Dec; 131:102833. Aburaki R, Fujiwara Y, Chida K, Horita N, Nagasaka M. PMID: 39369455.
-
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2024; 15:129-133. Arter ZL, Nagasaka M. PMID: 39224878; PMCID: PMC11367166.
-
Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC. Med. 2024 Aug 09; 5(8):852-855. Brazel D, Nagasaka M. PMID: 39127033.
-
ALINA: Another stepping stone toward a future of LDCT lung cancer screening in never-smokers? Med. 2024 Jul 12; 5(7):649-651. Nagasaka M, Ly CT, Ou SI. PMID: 39002534.
-
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA? Lung Cancer (Auckl). 2024; 15:115-121. Arter ZL, Nagasaka M. PMID: 39011085; PMCID: PMC11247161.
-
The APPLE trial in the evolving landscape of ctDNA monitoring. Transl Lung Cancer Res. 2024 Jun 30; 13(6):1432-1437. Brazel D, Nagasaka M. PMID: 38973953; PMCID: PMC11225046.
-
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckl). 2024; 15:87-114. Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ, Lim DWT, Santos ES, Shum E, Lau SCM, Lee JB, Calles A, Wu F, Lopes G, Sriuranpong V, Tanizaki J, Horinouchi H, Garassino MC, Popat S, Besse B, Rosell R, Soo RA. PMID: 38938224; PMCID: PMC11208875.
-
Race, age at diagnosis and histological characteristics of lung cancer in never-smokers (LCINS) and ever-smokers in low-dose computed tomography (LDCT) screening: a systematic review and meta-analysis. Transl Lung Cancer Res. 2024 May 31; 13(5):1047-1060. Triphuridet N, Nagasaka M, Shum E, Ou SI. PMID: 38854936; PMCID: PMC11157373.
-
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. Target Oncol. 2024 05; 19(3):297-301. Brazel D, Nagasaka M. PMID: 38739329; PMCID: PMC11111488.
-
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions. Lung Cancer (Auckl). 2024; 15:49-54. Kaakour D, Nagasaka M. PMID: 38685983; PMCID: PMC11056605.
-
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? Lung Cancer (Auckl). 2024; 15:41-47. Brazel D, Nagasaka M. PMID: 38633373; PMCID: PMC11021860.
-
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024 Apr; 25(4):439-454. Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA. PMID: 38547891.
-
Translational Research in ROS1-Positive NSCLC: Are We Moving Out of the Six Blind Men and the Elephant Stage? J Thorac Oncol. 2024 Apr; 19(4):525-527. Lee JB, Nagasaka M. PMID: 38582542.
-
PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer. Cancer Res. 2024 04 01; 84(7):1065-1083. Yamamoto T, Hayashida T, Masugi Y, Oshikawa K, Hayakawa N, Itoh M, Nishime C, Suzuki M, Nagayama A, Kawai Y, Hishiki T, Matsuura T, Naito Y, Kubo A, Yamamoto A, Yoshioka Y, Kurahori T, Nagasaka M, Takizawa M, Takano N, Kawakami K, Sakamoto M, Wakui M, Yamamoto T, Kitagawa Y, Kabe Y, Horisawa K, Suzuki A, Matsumoto M, Suematsu M. PMID: 38383964; PMCID: PMC10982647.
-
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer. Cancer Treat Rev. 2024 May; 126:102724. Grant C, Nagasaka M. PMID: 38636443.
-
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC. J Thorac Oncol. 2024 03; 19(3):380-384. Chen LN, Lee ATM, Nagasaka M, Ou SI. PMID: 38453326.
-
Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data. Expert Opin Investig Drugs. 2024 Feb; 33(2):79-84. Nagasaka M, Brazel D, Ou SI. PMID: 38224083.
-
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial's Impact. Lung Cancer (Auckl). 2024; 15:1-8. Arter ZL, Nagasaka M. PMID: 38298470; PMCID: PMC10825580.
-
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun; 19(6):928-940. Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. PMID: 38278303.
-
HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes. Clin Lung Cancer. 2024 Jun; 25(4):319-328.e1. Waliany S, Neal JW, Engel-Nitz N, Lam C, Lin F, Park L, Le L, Nagasaka M. PMID: 38403548.
-
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 01 11; 390(2):118-131. Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC, TRIDENT-1 Investigators. PMID: 38197815; PMCID: PMC11702311.
-
Oncogenic fusions: Targeting NTRK. Crit Rev Oncol Hematol. 2024 Feb; 194:104234. Hagopian G, Nagasaka M. PMID: 38122917.
-
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? Lung Cancer (Auckl). 2023; 14:101-109. Nagasaka M, Ou SI. PMID: 38111829; PMCID: PMC10725831.
-
Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central β-Sheet 6 [Cβ6] Mutation [L2086F]). J Thorac Oncol. 2024 May; 19(5):706-718. Ou SI, Hagopian GG, Zhang SS, Nagasaka M. PMID: 38070596.
-
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers. Mol Cancer Ther. 2023 12 01; 22(12):1422-1433. Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura SF, Mzannar Y, Azar I, Beal EW, Tobon ME, Kim SH, Beydoun R, Baloglu E, Senapedis W, El-Rayes BF, Philip PA, Mohammad RM, Shields AF, Al Hallak MN, Azmi AS. PMID: 37703579; PMCID: PMC10690049.
-
Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab. Allergy Asthma Clin Immunol. 2023 Oct 28; 19(1):93. Lopez M, Hagopian G, Doan L, Lee BJ, Rojek NW, Smith J, Ou SI, Demirdag YY, Nagasaka M. PMID: 37898814; PMCID: PMC10612162.
-
The development of amivantamab for the treatment of non-small cell lung cancer. Respir Res. 2023 Oct 25; 24(1):256. Brazel D, Nagasaka M. PMID: 37880647; PMCID: PMC10601226.
-
Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing. BMC Cancer. 2023 Oct 18; 23(1):1000. Nagasaka M, Zhang SS, Baca Y, Xiu J, Nieva J, Vanderwalde A, Swensen JJ, Spetzler D, Korn WM, Raez LE, Liu SV, Ou SI. PMID: 37853341; PMCID: PMC10585918.
-
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nat Med. 2023 10; 29(10):2577-2585. Cho BC, Kim DW, Spira AI, Gomez JE, Haura EB, Kim SW, Sanborn RE, Cho EK, Lee KH, Minchom A, Lee JS, Han JY, Nagasaka M, Sabari JK, Ou SI, Lorenzini P, Bauml JM, Curtin JC, Roshak A, Gao G, Xie J, Thayu M, Knoblauch RE, Park K. PMID: 37710001; PMCID: PMC10579096.
-
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer. Front Oncol. 2023; 13:1215524. Hsu R, Chen D, Xia B, Feldman R, Cozen W, Raez LE, Borghaei H, Kim C, Nagasaka M, Mamdani H, Vanderwalde AM, Lopes G, Socinski MA, Wozniak AJ, Spira AI, Liu SV, Nieva JJ. PMID: 37700839; PMCID: PMC10494442.
-
Neoadjuvant therapy in non-small cell lung cancer. Crit Rev Oncol Hematol. 2023 Oct; 190:104080. Grant C, Hagopian G, Nagasaka M. PMID: 37532102.
-
Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. Transl Oncol. 2023 Oct; 36:101744. Nagasaka M, Brazel D, Baca Y, Xiu J, Al-Hallak MN, Kim C, Nieva J, Swensen JJ, Spetzler D, Korn WM, Socinski MA, Raez LE, Halmos B, Ou SI. PMID: 37516008; PMCID: PMC10410168.
-
Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations. Cancer Manag Res. 2023; 15:627-634. Ahn J, Nagasaka M. PMID: 37457376; PMCID: PMC10349595.
-
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review. Cancers (Basel). 2023 Jul 10; 15(14). Hsu R, Benjamin DJ, Nagasaka M. PMID: 37509224; PMCID: PMC10377299.
-
From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Crit Rev Oncol Hematol. 2023 Jul; 187:104019. Ou SI, Lee ATM, Nagasaka M. PMID: 37187318.
-
Proteolysis targeting chimeras in non-small cell lung cancer. Cancer Treat Rev. 2023 Jun; 117:102561. Hagopian G, Grant C, Nagasaka M. PMID: 37178629.
-
CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC. Lung Cancer (Auckl). 2023; 14:41-46. Lee ATM, Nagasaka M. PMID: 37138950; PMCID: PMC10150033.
-
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code. Lung Cancer (Auckl). 2023; 14:27-30. Zhang SS, Lee A, Nagasaka M. PMID: 37101895; PMCID: PMC10123019.
-
Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM). Clin Lung Cancer. 2023 09; 24(6):563-567. Wozniak AJ, Schneider B, Kalemkerian GP, Daly B, Chen W, Ventimiglia J, Nagasaka M, Zauderer MG. PMID: 37301693; PMCID: PMC11233026.
-
Penetrating the central nervous system sanctuary of KRAS, a target once thought "undruggable". Transl Lung Cancer Res. 2023 Apr 28; 12(4):665-668. Nagasaka M, Azmi AS. PMID: 37197620; PMCID: PMC10183396.
-
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers. bioRxiv. 2023 Mar 27. Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura S, Mzannar Y, Azar I, Beal E, Tobon M, Kim S, Beydoun R, Baloglu E, Senapedis W, El-Rayes B, Philip PA, Mohammad RM, Shields AF, Al-Hallak MN, Azmi AS. PMID: 37034616; PMCID: PMC10081231.
-
TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors. Future Oncol. 2023 Jan; 19(2):123-135. Nagasaka M, Ohe Y, Zhou C, Choi CM, Yang N, Liu G, Felip E, Pérol M, Besse B, Nieva J, Raez L, Pennell NA, Dimou A, Marinis F, Ciardiello F, Seto T, Hu Z, Pan M, Wang W, Li S, Ou SI. PMID: 36877099.
-
Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in Asian Female Never-Smokers Is as Efficacious in Detecting Lung Cancer as in Asian Male Ever-Smokers: A Systematic Review and Meta-Analysis. J Thorac Oncol. 2023 06; 18(6):698-717. Triphuridet N, Zhang SS, Nagasaka M, Gao Y, Zhao JJ, Syn NL, Hanaoka T, Ou SI, Shum E. PMID: 36775191.
-
Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes. Hematol Oncol Stem Cell Ther. 2023 Jan 17; 16(2):144-150. Banavasi H, Kim S, Alkassis S, Daoud A, Laktineh A, Nagasaka M, Sukari A, Soubani AO. PMID: 34688626.
-
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckl). 2023; 14:1-9. Brazel D, Ou SI, Nagasaka M. PMID: 36636263; PMCID: PMC9831070.
-
Neptune, the Next Pluto?-Durvalumab and Tremelimumab Face Challenges in Entering the NSCLC Space. J Thorac Oncol. 2023 01; 18(1):29-30. Ahn JY, Nagasaka M. PMID: 36543434.
-
In Response to Dr. Steven Sorscher. JTO Clin Res Rep. 2023 Jan; 4(1):100453. Zhang SS, Schrock AB, Nagasaka M, Ou SI. PMID: 36654883; PMCID: PMC9841026.
-
Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer. JTO Clin Res Rep. 2023 Feb; 4(2):100452. Anwar K, Nguyen L, Nagasaka M, Ou SI, Chan A. PMID: 36568522; PMCID: PMC9759297.
-
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022 Dec 09; 6(1):91. Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, Ross JS, Frampton GM, Napalkov P, Montesion M, Schutzman JL, Ye X, Hegde PS, Nagasaka M, Oxnard GR, Sokol ES, Ou SI, Shi Z. PMID: 36494601; PMCID: PMC9734185.
-
CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib? J Thorac Oncol. 2023 Feb; 18(2):139-142. Nagasaka M, Ou SI. PMID: 36460598.
-
The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy. Neurol Int. 2022 Nov 21; 14(4):981-990. Shibata S, Sakurai K, Tachikawa K, Ko R, Hino S, Fukano T, Isahaya K, Haraguchi T, Yamauchi J, Tanabe K, Nagasaka M, Hagiwara Y, Shimizu T, Akiyama H, Kobayashi Y, Hasegawa Y, Yamano Y. PMID: 36412699; PMCID: PMC9680239.
-
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib. Lung Cancer (Auckl). 2022; 13:75-80. Brazel D, Arter Z, Nagasaka M. PMID: 36387582; PMCID: PMC9662012.
-
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options. BioDrugs. 2022 Nov; 36(6):717-729. Brazel D, Kroening G, Nagasaka M. PMID: 36255589; PMCID: PMC9649507.
-
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 03; 165(3):828-839.e5. Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Baciewicz F, Nagasaka M, Pass HI, Schulze K, Johnson A, Bunn PA, Johnson BE, Kris MG, Kwiatkowski DJ, Wistuba II, Chaft JE, Carbone DP, Lee JM. PMID: 36369159; PMCID: PMC10288861.
-
Validation of deep learning-based computer-aided detection software use for interpretation of pulmonary abnormalities on chest radiographs and examination of factors that influence readers' performance and final diagnosis. Jpn J Radiol. 2023 Jan; 41(1):38-44. Toda N, Hashimoto M, Iwabuchi Y, Nagasaka M, Takeshita R, Yamada M, Yamada Y, Jinzaki M. PMID: 36121622.
-
Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)? J Clin Oncol. 2023 02 01; 41(4):742-744. Benjamin DJ, Nagasaka M. PMID: 36095291.
-
Potential role of HTLV-1 Tax-specific cytotoxic t lymphocytes expressing a unique t-cell receptor to promote inflammation of the central nervous system in myelopathy associated with HTLV-1. Front Immunol. 2022; 13:993025. Tanaka Y, Sato T, Yagishita N, Yamauchi J, Araya N, Aratani S, Takahashi K, Kunitomo Y, Nagasaka M, Kanda Y, Uchimaru K, Morio T, Yamano Y. PMID: 36081501; PMCID: PMC9446235.
-
Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 08 15; 28(16):3464-3472. Leddon JL, Gulati S, Haque S, Allen C, Palackdharry S, Mathews M, Kurtzweil N, Riaz MK, Takiar V, Nagasaka M, Patil Y, Zender C, Tang A, Cervenka B, McGrath J, Korn WM, Hinrichs BH, Jandarov R, Harun N, Sukari A, Wise-Draper TM. PMID: 35653116; PMCID: PMC9378458.
-
A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature. JTO Clin Res Rep. 2022 Sep; 3(9):100387. Zhang SS, Lee JK, Tukachinsky H, Schrock AB, Nagasaka M, Ou SI. PMID: 36061833; PMCID: PMC9429789.
-
Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clin Res Rep. 2022 Sep; 3(9):100381. Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, Ma PC, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B. PMID: 36082279; PMCID: PMC9445394.
-
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review. Drugs. 2022 Jun; 82(9):979-987. Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. PMID: 35759121; PMCID: PMC9276583.
-
Clinical progress of KRAS-targeted therapies: what next? Future Med Chem. 2022 08; 14(15):1107-1110. Nagasaka M, Azmi AS. PMID: 35758004.
-
African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer. Head Neck. 2022 10; 44(10):2069-2076. Shao YF, Kim S, Cramer JD, Farhat D, Hotaling J, Raza SN, Yoo G, Lin HS, Kim H, Sukari A, Nagasaka M. PMID: 35713967; PMCID: PMC9543059.
-
The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. Front Oncol. 2022; 12:859892. Liu SV, Nagasaka M, Stefaniak V, Gruver K, Lin Y, Ferry D, Socinski MA, Zhang L. PMID: 35756655; PMCID: PMC9226396.
-
Preface. Cancer Metastasis Rev. 2022 06; 41(2):245-246. Nagasaka M, Chen G. PMID: 35725839.
-
Correction to: Connecting the human microbiome and pancreatic cancer. Cancer Metastasis Rev. 2022 Jun; 41(2):333. Sexton RE, Uddin MH, Bannoura S, Khan HY, Mzannar Y, Li Y, Aboukameel A, Al-Hallak MN, Al-Share B, Mohamed A, Nagasaka M, El-Rayes B, Azmi AS. PMID: 35536453; PMCID: PMC9486138.
-
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC. Lung Cancer (Auckl). 2022; 13:47-52. Brazel D, Nagasaka M. PMID: 35615402; PMCID: PMC9126226.
-
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Lung Cancer (Auckl). 2022; 13:33-45. Brazel D, Zhang S, Nagasaka M. PMID: 35592355; PMCID: PMC9113513.
-
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029. Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. PMID: 35165101; PMCID: PMC9365353.
-
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers. Cancer Res Commun. 2022 05; 2(5):342-352. Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS. PMID: 35573474; PMCID: PMC9105196.
-
NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med. 2022 07; 11(13):2541-2549. Wang H, Li ZW, Ou Q, Wu X, Nagasaka M, Shao Y, Ou SI, Yang Y. PMID: 35506567; PMCID: PMC9249987.
-
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022 May; 106:102393. Abuhelwa Z, Alloghbi A, Nagasaka M. PMID: 35472631; PMCID: PMC12582167.
-
Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy. Front Med (Lausanne). 2022; 9:879379. Kimura M, Yamauchi J, Sato T, Yagishita N, Araya N, Aratani S, Tanabe K, Horibe E, Watanabe T, Coler-Reilly A, Nagasaka M, Akasu Y, Kaburagi K, Kikuchi T, Shibata S, Matsumoto H, Koseki A, Inoue S, Takata A, Yamano Y. PMID: 35479934; PMCID: PMC9036434.
-
Connecting the Human Microbiome and Pancreatic Cancer. Cancer Metastasis Rev. 2022 06; 41(2):317-331. Sexton RE, Uddin MH, Bannoura S, Khan HY, Mzannar Y, Li Y, Aboukameel A, Al-Hallak MN, Al-Share B, Mohamed A, Nagasaka M, El-Rayes B, Azmi AS. PMID: 35366155; PMCID: PMC8976105.
-
Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer. Future Oncol. 2022 May; 18(16):1963-1977. Nagasaka M, Molife C, Cui ZL, Stefaniak V, Li X, Kim S, Lee HY, Beyrer J, Blumenschein G. PMID: 35354280.
-
ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression? Lung Cancer (Auckl). 2022; 13:13-21. Nagasaka M, Ou SI. PMID: 35378922; PMCID: PMC8976558.
-
Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations. Clin Lung Cancer. 2022 06; 23(4):333-344. Harris JP, Fujimoto DK, Nagasaka M, Ku E, Harada G, Keshava H, Mahtabifard A, Longoria J, Patel N, Seyedin S, Simon A, Chen A. PMID: 35256282.
-
Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy. J Thorac Oncol. 2022 02; 17(2):182-185. Nagasaka M, Ou SI. PMID: 35074224.
-
Clinical utility of the Bosniak classification version 2019: Diagnostic value of adding magnetic resonance imaging to computed tomography examination. Eur J Radiol. 2022 Mar; 148:110163. Arita Y, Yoshida S, Kwee TC, Edo H, Kufukihara R, Shigeta K, Nagasaka M, Takeshita R, Okamura H, Ueda R, Ishii R, Okuda S, Fujii Y. PMID: 35066340.
-
Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P). Viruses. 2022 01 12; 14(1). Yamauchi J, Tanabe K, Sato T, Nakagawa M, Matsuura E, Tsuboi Y, Tamaki K, Sakima H, Ishihara S, Ohta Y, Matsumoto N, Kono K, Yagishita N, Araya N, Takahashi K, Kunitomo Y, Nagasaka M, Coler-Reilly A, Hasegawa Y, Araujo A, Jacobson S, Grassi MFR, Galvão-Castro B, Bland M, Taylor GP, Martin F, Yamano Y. PMID: 35062340; PMCID: PMC8780460.
-
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. Trends Cancer. 2022 03; 8(3):242-258. Nagasaka M, Ou SI. PMID: 34996744.
-
Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. Lung Cancer. 2022 02; 164:52-55. Nagasaka M, Balmanoukian AS, Madison R, Zhang SS, Klempner SJ, Ou SI. PMID: 35032819.
-
Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021 Dec 07; 12(25):2449-2458. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ. PMID: 34917263; PMCID: PMC8664394.
-
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021; 12:133-138. Brazel D, Nagasaka M. PMID: 34880698; PMCID: PMC8648093.
-
Incidence of Second Primary Lung Cancer After Low-Dose Computed Tomography vs Chest Radiography Screening in Survivors of Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021 12 01; 147(12):1071-1078. Cramer JD, Grauer J, Sukari A, Nagasaka M. PMID: 34709369; PMCID: PMC8554690.
-
KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev. 2021 Dec; 101:102309. Nagasaka M, Potugari B, Nguyen A, Sukari A, Azmi AS, Ou SI. PMID: 34715449.
-
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. Clin Lung Cancer. 2022 01; 23(1):52-59. Nagasaka M, Singh V, Baca Y, Sukari A, Kim C, Mamdani H, Spira AI, Uprety D, Bepler G, Kim ES, Raez LE, Pai SG, Ikpeazu C, Oberley M, Feldman R, Xiu J, Korn WM, Wozniak AJ, Borghaei H, Liu SV. PMID: 34801409.
-
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021; 12:115-122. Zhang SS, Nagasaka M. PMID: 34675734; PMCID: PMC8504654.
-
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021; 12:103-114. Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, Sukari A, Nagasaka M. PMID: 34675733; PMCID: PMC8507417.
-
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 01 20; 386(3):241-251. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA, DESTINY-Lung01 Trial Investigators. PMID: 34534430; PMCID: PMC9066448.
-
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021 12; 20(12):2577-2584. Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. PMID: 34518295; PMCID: PMC9662933.
-
Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev. 2021 09; 40(3):819-835. Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. PMID: 34499267; PMCID: PMC8556325.
-
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2021 10; 160:92-98. Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. PMID: 34482103; PMCID: PMC8853639.
-
Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? Transl Oncol. 2021 Nov; 14(11):101191. Ou SI, Nagasaka M, Brazel D, Hou Y, Zhu VW. PMID: 34365220; PMCID: PMC8353359.
-
Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis. Head Neck. 2021 11; 43(11):3681-3696. Quan DL, Sukari A, Nagasaka M, Kim H, Cramer JD. PMID: 34323332.
-
p16 positive oropharyngeal small cell cancer: A case report. Oral Oncol. 2021 10; 121:105391. Al Masalmeh N, Kukreja G, Zaiem F, Raza SN, Kim H, Nagasaka M, Sukari A. PMID: 34187735.
-
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer. 2021 08; 158:126-136. Zhang SS, Nagasaka M, Zhu VW, Ou SI. PMID: 34175504.
-
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. J Clin Oncol. 2021 09 01; 39(25):2791-2802. Drilon A, Duruisseaux M, Han JY, Ito M, Falcon C, Yang SR, Murciano-Goroff YR, Chen H, Okada M, Molina MA, Wislez M, Brun P, Dupont C, Branden E, Rossi G, Schrock A, Ali S, Gounant V, Magne F, Blum TG, Schram AM, Monnet I, Shih JY, Sabari J, Pérol M, Zhu VW, Nagasaka M, Doebele R, Camidge DR, Arcila M, Ou SI, Moro-Sibilot D, Rosell R, Muscarella LA, Liu SV, Cadranel J. PMID: 34077268; PMCID: PMC8407651.
-
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021 06 01; 20(1):82. Nagasaka M, Uddin MH, Al-Hallak MN, Rahman S, Balasubramanian S, Sukari A, Azmi AS. PMID: 34074295; PMCID: PMC8170728.
-
Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer. 2021 07; 157:147-155. Zhu VW, Zhao JJ, Gao Y, Syn NL, Zhang SS, Ou SI, Bauer KA, Nagasaka M. PMID: 34049720.
-
Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer. Clin Lung Cancer. 2021 11; 22(6):e842-e850. Fisher A, Kim S, Farhat D, Belzer K, Milczuk M, French C, Mamdani H, Sukari A, Baciewicz F, Schwartz AG, Wozniak A, Nagasaka M. PMID: 34053862; PMCID: PMC8536802.
-
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. J Thorac Oncol. 2021 04; 16(4):532-536. Nagasaka M, Ou SI. PMID: 33781444.
-
Utility of transoral motion-mode ultrasonography to detect tongue fasciculation in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2021 06; 63(6):909-913. Hagiwara Y, Shimizu T, Yanagisawa T, Akasu Y, Kaburagi K, Kikuchi T, Shibata S, Matsumoto H, Soga K, Tsuchihashi Y, Nagasaka M, Sasaki N, Maki F, Shiraishi M, Akiyama H, Hasegawa Y, Yamano Y. PMID: 33675079.
-
Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. Sci Rep. 2021 03 11; 11(1):5639. Elliott A, Saul M, Zeng J, Marshall JL, Kim ES, Nagasaka M, Lenz HJ, Schwartzberg L, Spetzler D, Abraham J, Xiu J, Stafford P, Michael Korn W. PMID: 33707526; PMCID: PMC7952699.
-
Forget me not - Incorporating standard chemotherapy in an exciting era of clinical trials. Oral Oncol. 2021 05; 116:105160. Nguyen A, Nagasaka M. PMID: 33487535.
-
Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. JTO Clin Res Rep. 2021 Feb; 2(2):100132. Ou SI, Xiu J, Nagasaka M, Xia B, Zhang SS, Zhang Q, Swensen JJ, Spetzler D, Korn WM, Zhu VW, Liu SV. PMID: 34589990; PMCID: PMC8474258.
-
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021 05; 16(5):740-763. Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SI. PMID: 33338652.
-
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2020 Dec; 9(6):2521-2534. Xia B, Nagasaka M, Zhu VW, Ou SI, Soo RA. PMID: 33489815; PMCID: PMC7815371.
-
STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib. JTO Clin Res Rep. 2021 Feb; 2(2):100125. Nagasaka M, Sarvadevabatla N, Iwata S, Ge Y, Sukari A, Klosowski C, Yanagihara R. PMID: 34589985; PMCID: PMC8474477.
-
A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. JTO Clin Res Rep. 2021 Jan; 2(1):100116. Zhu VW, Nagasaka M, Madison R, Schrock AB, Cui J, Ou SI. PMID: 34589977; PMCID: PMC8474455.
-
PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy. Clin Lung Cancer. 2021 01; 22(1):e51-e53. Nagasaka M, Fisher A, Chowdhury T, Ge Y, Sukari A. PMID: 32893122.
-
Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet J Rare Dis. 2020 07 03; 15(1):175. Yamakawa N, Yagishita N, Matsuo T, Yamauchi J, Ueno T, Inoue E, Takata A, Nagasaka M, Araya N, Hasegawa D, Coler-Reilly A, Tsutsumi S, Sato T, Araujo A, Casseb J, Gotuzzo E, Jacobson S, Martin F, Puccioni-Sohler M, Taylor GP, Yamano Y, Japan Clinical Research Group on HAM/TSP. PMID: 32620176; PMCID: PMC7333329.
-
Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations. Mol Oncol. 2020 08; 14(8):1731-1739. Fan Y, Qiu J, Yu R, Cao R, Chen X, Ou Q, Wu X, Shao YW, Nagasaka M, Zhang J, Ou SI. PMID: 32478891; PMCID: PMC7400783.
-
Is NRG2α Fusion a "Doppelgänger" to NRG1α/β Fusions in Oncology? J Thorac Oncol. 2020 06; 15(6):878-880. Nagasaka M, Ou SI. PMID: 32471560.
-
Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis. Proc Natl Acad Sci U S A. 2020 05 26; 117(21):11685-11691. Nagasaka M, Yamagishi M, Yagishita N, Araya N, Kobayashi S, Makiyama J, Kubokawa M, Yamauchi J, Hasegawa D, Coler-Reilly ALG, Tsutsumi S, Uemura Y, Arai A, Takata A, Inoue E, Hasegawa Y, Watanabe T, Suzuki Y, Uchimaru K, Sato T, Yamano Y. PMID: 32393644; PMCID: PMC7260950.
-
A user's guide to lorlatinib. Crit Rev Oncol Hematol. 2020 Jul; 151:102969. Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SI. PMID: 32416346.
-
The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series). Oral Oncol. 2020 10; 109:104744. Sukari A, Kukreja G, Nagasaka M, Shukairy MK, Yoo G, Lin HS, Hotaling J, Kim H. PMID: 32402656.
-
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. J Thorac Oncol. 2020 09; 15(9):1484-1496. Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, Ang YL, Ock CY, Tchekmedyian N, Ou SI, Syn NL, Reungwetwattana T, Lin CC, Soo RA. PMID: 32360579.
-
A Catalog of 5' Fusion Partners in ROS1-Positive NSCLC Circa 2020. JTO Clin Res Rep. 2020 Sep; 1(3):100048. Ou SI, Nagasaka M. PMID: 34589944; PMCID: PMC8474457.
-
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020 07; 145:186-194. Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, Xia B, Zhu VW, Nagasaka M, Yang Y, Li Y, Qiu W, Ying J, Ou SI, Wang Y. PMID: 32336530.
-
Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep. 2020 Mar; 1(1):100015. Ou SI, Zhu VW, Nagasaka M. PMID: 34589917; PMCID: PMC8474466.
-
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat Rev. 2020 Mar; 84:101974. Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. PMID: 32014824; PMCID: PMC7041424.
-
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. Lung Cancer (Auckl). 2020; 11:13-18. Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI. PMID: 32021525; PMCID: PMC6970251.
-
COPD and lung cancer incidence in the Women's Health Initiative Observational Study: A brief report. Lung Cancer. 2020 03; 141:78-81. Nagasaka M, Lehman A, Chlebowski R, Haynes BM, Ho G, Patel M, Sakoda LC, Schwartz AG, Simon MS, Cote ML. PMID: 31958598; PMCID: PMC8898572.
-
Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. Int J Mol Sci. 2019 Dec 29; 21(1). Khan HY, Ge J, Nagasaka M, Aboukameel A, Mpilla G, Muqbil I, Szlaczky M, Chaker M, Baloglu E, Landesman Y, Mohammad RM, Azmi AS, Sukari A. PMID: 31905765; PMCID: PMC6982268.
-
Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):305-311. Bumma N, Nagasaka M, Hemingway G, Miyashita H, Chowdhury T, Kim S, Vankayala HM, Ahmed S, Jasti P. PMID: 32144026.
-
Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review. Crit Rev Oncol Hematol. 2020 Jan; 145:102841. Nagasaka M, Sexton R, Alhasan R, Rahman S, Azmi AS, Sukari A. PMID: 31884204.
-
Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids. J Neurol Neurosurg Psychiatry. 2020 03; 91(3):321-323. Yamauchi J, Sato T, Yagishita N, Araya N, Hasegawa D, Tsutsumi S, Nagasaka M, Coler-Reilly A, Inoue E, Takata A, Hasegawa Y, Yamano Y. PMID: 31662348.
-
Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. Orphanet J Rare Dis. 2019 10 21; 14(1):227. Tsutsumi S, Sato T, Yagishita N, Yamauchi J, Araya N, Hasegawa D, Nagasaka M, Coler-Reilly ALG, Inoue E, Takata A, Yamano Y. PMID: 31639014; PMCID: PMC6802124.
-
Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response? Oral Oncol. 2020 02; 101:104435. Sukari A, Nagasaka M. PMID: 31635973.
-
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):247-254. Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, Shao YW, Hu X, Ou SI. PMID: 31761448.
-
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors. Lung Cancer (Auckl). 2019; 10:95-105. Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A. PMID: 31572037; PMCID: PMC6750163.
-
Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Front Microbiol. 2019; 10:2110. Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Araya N, Yamauchi J, Coler-Reilly ALG, Nagasaka M, Hasegawa Y, Yamano Y, Tsuboi Y. PMID: 31572323; PMCID: PMC6749079.
-
Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report. Oral Oncol. 2019 12; 99:104350. Abdallah N, Nagasaka M, Chowdhury T, Raval K, Hotaling J, Sukari A. PMID: 31277904.
-
Neuregulin 1 Fusion-Positive NSCLC. J Thorac Oncol. 2019 08; 14(8):1354-1359. Nagasaka M, Ou SI. PMID: 31128291.
-
Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients. Clin Otolaryngol. 2019 07; 44(4):639-643. Sukari A, Nagasaka M, Diab M, Al Sibai K, Atassi B, Elayoubi JA, Kim S, Küçük Ö. PMID: 30784192; PMCID: PMC6844146.
-
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. Anticancer Res. 2019 Feb; 39(2):781-790. Sukari A, Nagasaka M, Alhasan R, Patel D, Wozniak A, Ramchandren R, Vaishampayan U, Weise A, Flaherty L, Jang H, Kim S, Gadgeel S. PMID: 30711957; PMCID: PMC6886239.
-
Unleash the power of the mighty T cells-basis of adoptive cellular therapy. Crit Rev Oncol Hematol. 2019 Apr; 136:1-12. Sukari A, Abdallah N, Nagasaka M. PMID: 30878123.
-
Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer (Auckl). 2018; 9:85-90. Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A. PMID: 30498383; PMCID: PMC6207227.
-
Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. Front Microbiol. 2018; 9:1651. Sato T, Yagishita N, Tamaki K, Inoue E, Hasegawa D, Nagasaka M, Suzuki H, Araya N, Coler-Reilly A, Hasegawa Y, Tsuboi Y, Takata A, Yamano Y. PMID: 30090093; PMCID: PMC6068401.
-
The allure of 'ALUR'. Ann Oncol. 2018 06 01; 29(6):1344-1346. Nagasaka M, Zhu VW, Ou SI. PMID: 29688274.
-
Is this really just "fatigue"? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. Clin Case Rep. 2018 Jul; 6(7):1278-1281. Nagasaka M, Abdallah N, Samantray J, Sukari A. PMID: 29988586; PMCID: PMC6028360.
-
Liquid Biopsy to Identify Actionable Genomic Alterations. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:978-997. Ou SI, Nagasaka M, Zhu VW. PMID: 30231331; PMCID: PMC6865813.
-
Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. Oral Oncol. 2018 05; 80:100-102. Sukari A, Nagasaka M, Abdallah N. PMID: 29605290.
-
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 2018 01; 18(1):63-70. Nagasaka M, Gadgeel SM. PMID: 29168933; PMCID: PMC6863145.
-
EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing. J Natl Compr Canc Netw. 2017 10; 15(10):1188-1192. Sukari A, Nagasaka M, Wakeling E. PMID: 28982744.
-
Retreatment With Osimertinib Following Pneumonitis. Clin Lung Cancer. 2018 01; 19(1):e53-e55. Nagasaka M, Gadgeel SM. PMID: 28736180.
-
Histologic Transformation in NSCLC with PD-1 therapy. J Thorac Oncol. 2017 09; 12(9):e133-e134. Nagasaka M, Pansare RS, Abdulfatah E, Guan H, Tranchida P, Gadgeel SM. PMID: 28502723.
-
Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. Laryngoscope. 2017 10; 127(10):2260-2264. Nagasaka M, Zaki M, Issa M, Kim H, Abrams J, Sukari A. PMID: 28271529; PMCID: PMC6853181.
-
Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site. Clin Genitourin Cancer. 2017 08; 15(4):e713-e717. Nagasaka M, Kukreja G, Abdulfatah E, Vaishampayan U, Sukari A. PMID: 28024951.
-
PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. J Immunother Cancer. 2016; 4:83. Nagasaka M, Zaki M, Kim H, Raza SN, Yoo G, Lin HS, Sukari A. PMID: 27895920; PMCID: PMC5109767.
-
Cancer Immunology and Immunotherapy. Anticancer Res. 2016 11; 36(11):5593-5606. Sukari A, Nagasaka M, Al-Hadidi A, Lum LG. PMID: 27793882.
-
Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer. Oncology (Williston Park). 2014 Jun; 28(6):526, 528, 530, 534. Saxena A, Nagasaka M, Li Z, Becker DJ, Levy BP. PMID: 25134330.
-
Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. J Hypertens. 2001 Oct; 19(10):1877-82. Kohzuki M, Kamimoto M, Wu XM, Xu HL, Kawamura T, Mori N, Nagasaka M, Kurosawa H, Minami N, Kanazawa M, Saito T, Yoshida K. PMID: 11593110.
-
Effects of a two-week, hospitalized phase II cardiac rehabilitation program on physical capacity, lipid profiles and psychological variables in patients with acute myocardial infarction. Jpn Circ J. 2001 Feb; 65(2):87-93. Yoshida T, Yoshida K, Yamamoto C, Nagasaka M, Tadaura H, Meguro T, Sato T, Kohzuki MM. PMID: 11216831.
-
Renal-protective effect of nondepressor dose of cicletanine in diabetic rats with hypertension. Am J Hypertens. 2000 Mar; 13(3):298-306. Kohzuki M, Wu XM, Kamimoto M, Yoshida K, Nagasaka M, Kanazawa M, Yasujima M, Saito T, Sato T. PMID: 10777035.
-
Comparison of resting beta-methyl-iodophenyl pentadecanoic acid (BMIPP) and thallium-201 tomography using quantitative polar maps in patients with unstable angina. Jpn Circ J. 1997 Feb; 61(2):133-8. Suzuki A, Takada Y, Nagasaka M, Kato R, Watanabe T, Shimokata K, Yasui S. PMID: 9070968.
-
Antley-Bixler syndrome: a disorder characterized by congenital synostosis of the elbow joint and the cranial suture. J Pediatr Orthop. 1996 Mar-Apr; 16(2):243-6. Kitoh H, Nogami H, Oki T, Arao K, Nagasaka M, Tanaka Y. PMID: 8742293.
-
Estimation of anterior infarct size with body surface QRST integral maps in the presence of abnormal ventricular activation sequence in dogs. Am Heart J. 1993 Feb; 125(2 Pt 1):291-300. Ichihara Y, Hirai M, Hayashi H, Tomita Y, Adachi M, Suzuki A, Tsuda M, Nagasaka M, Saito H. PMID: 8427119.
-
Small differences among body surface and epicardial QRST integral maps recorded during normal activation and experimentally simulated left bundle branch block or preexcitation in canine hearts. J Electrocardiol. 1992 Oct; 25(4):315-22. Ichihara Y, Hayashi H, Tomita Y, Adachi M, Kondo K, Suzuki A, Nagasaka M, Hirai M, Saito H. PMID: 1402517.
-
[Quantitative evaluations of disturbances in cerebrospinal fluid circulation with indium-111 cisternography. A clinical study]. Neurol Med Chir (Tokyo). 1987 Jun; 27(6):526-32. Kuchiwaki H, Nagasaka M, Itoh J, Takada S, Ishiguri H, Kageyama N, Nishino M, Kameyama H. PMID: 2448672.
-
Allogeneic bone marrow transplantation in children: Tokai experience 1982 to 1984. Tokai J Exp Clin Med. 1985 Jun; 10(2-3):147-58. Kato S, Hoshi N, Nagasaka M, Muranaka S, Yabe H, Kimura M. PMID: 3010509.
-
Phenotypic reversion of D+ and D- mutant clones in mouse myeloid leukemia. Kobe J Med Sci. 1983 Oct; 29(5):129-42. Maeda S, Chen HL, Nagasaka M, Sugiyama T. PMID: 6583460.
-
Four cases of t(4;11) acute leukemia and its myelomonocytic nature in infants. Blood. 1983 Jun; 61(6):1174-81. Nagasaka M, Maeda S, Maeda H, Chen HL, Kita K, Mabuchi O, Misu H, Matsuo T, Sugiyama T. PMID: 6340755.
-
Establishment and cytological characteristics of two in vitro T-cell lines derived from a child with acute lymphatic leukemia and a man with adult T-cell leukemia in Japan. Int J Cancer. 1982 Aug 15; 30(2):173-80. Nagasaka M, Maeda S, Mabuchi O, Takubo T, Nasu K, Wano Y, Sugiyama T. PMID: 6982237.
-
QT duration and plasma electrolytes (Ca, Na, and K) in uremic patients. Jpn Heart J. 1972 May; 13(3):187-94. Nagasaka M, Yokosuka H, Yamanaka T, Sato T, Nakamura K. PMID: 4538251.
-
CLINICAL FEATURE OF MYOCARDIAL INFARCTION IN JAPAN. Jpn Heart J. 1964 Nov; 5:497-511. YOSHITOSHI Y, HANAOKA W, NAGASAKA M, MIYASHITA H, YAMAGUCHI A, ITO T, WATANABE S, OSHIMA M, SHINOHARA Y. PMID: 14250894.
US